Also: All the news and watercooler chat from Fortune.

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

The 2025-26 Pfizer COVID-19 vaccine is about 57% effective against emergency department/urgent care (ED/UC) visits and 54% ...

But while the rankings held steady, the operating environment has changed quickly to reinforce the value of being in good standing with physicians.

Pfizer (PFE) closed the most recent trading day at $26.50, moving +2.4% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.41%. At the same time, ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Pfizer Inc. has a rare 3-year tariff exemption and margin defense amid global price parity risks. Click here to read an ...

Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...